The aim of the group "Biomarker Development" led by PD Dr. Jürgen Dukart is to identify, validate and integrate novel neuroimaging and digital biomarkers that can be applied for early detection and treatment evaluation of changes in brain organization in advanced age as well as in neurological and psychiatric diseases.
Development of novel biomarkers that improve diagnosis, prognosis and monitoring of disease progression is an essential step towards the development of successful treatment options for neuropsychiatric diseases.
The group focuses on understanding the underlying neuropathology of specific dysfunctions. To this end, different biomarker technologies, such as multimodal neuroimaging, and sensor-based evaluations will be combined. The combination of data from own clinical studies and large public databases with machine learning enables the identification of new biomarkers, and from a theoretical point of view a more detailed understanding of the underlying symptoms.
Prospective validation of these technologies and biomarkers in local studies is critical for their success in terms of integration into everyday research and clinical practice. As the application of innovative analysis methods to large amounts of data is an important aspect, this group strongly collaborates with the group Applied Machine Learning. In terms of content, there is a strong synergy with the group Brain Variability, especially with regard to prognostic applications.
Dr. Jürgen Dukart
Building 14.6 / Room 2039